Life Sciences

GSK’s HIV prevention drug moves toward marketing approv...

GSK Plc announced on Monday that ViiV Healthcare, its subsidiary focused on HIV ...

J&J, GSK Indicate Cabenuva Preference Over Gilead Rival

In order to make Cabenuva the conventional treatment choice for HIV, Johnson & J...

Glucotrack’s CGM Implant Clears First Feasibility Study

Continuous glucose monitors (CGMs) have become a breakthrough in diabetes manage...

Eli Lilly’s Obesity Drug Performs Well in Two Late-Stag...

Eli Lilly announced that its experimental obesity medicine helped patients lose ...

Vietnam Gives Green Light to First African Swine Fever ...

According to a statement released by the government on Monday, Vietnam has given...

FDA approves Tarsus’ Xdemvy, the first treatment for a ...

Tarsus Pharmaceuticals has achieved a significant milestone with the FDA approva...

Verrica Scores FDA Approval for Ycanth at the Cost of a...

Verrica Pharmaceuticals has finally obtained approval from the Food and Drug Adm...

Bavarian Nordic Fails Phase 3 Trial, Leaving the RSV Race

Bavarian Nordic, a Danish pharmaceutical company, suffered a significant setback...

Mirati’s KRAS Inhibitor Krazi Fails to Make It in Europe

Mirati Therapeutics has learned the hard way that a clearance from the U.S. Food...

American Society of Retinal Specialists raise concerns ...

The American Society of Retinal Specialists (ASRS) issued a letter to doctors ra...

FDA approves MeMed’s bacteria-versus-virus blood test t...

MeMed, an infectious disease diagnostic company, has achieved a significant mile...

ADC Therapeutics terminates Zynlonta study after FDA pu...

ADC Therapeutics has decided to terminate its Zynlonta trial after the FDA impos...

Novartis Acquires DTx Pharma in a Deal Potentially Wort...

Swiss pharmaceutical firm Novartis said on Monday that it has purchased biotechn...

BridgeBio’s acoramidis shows positive results in phase ...

Late-stage study results from BridgeBio’s phase 3 trial of its heart disease dru...

Alnylam’s RNAi approach reaches the biomarker target

Alnylam has made significant progress in combating Alzheimer’s disease using its...

Pharmaceutical Layoffs Begin as FibroGen And Boston Sci...

It seems like pharmaceutical layoffs are in full flow as FibroGen and Boston Sci...